天利控股集團(00117.HK)公佈集團提起的二十項訴訟最新進展
格隆匯 4 月 23日丨天利控股集團(00117.HK)公吿,內容有關集團對廣東微容電子科技有限公司("廣東微容")、深圳微容電子有限公司及深圳市微容電子元器件有限公司(統稱"被吿人")提起20項訴訟,以就其於片式多層陶瓷電容器("MLCC")生產程序兩項發明專利及18項實用新型專利申索其權利。
於2021年4月21日,公司已接獲廣州知識產權法院的通知,法院已將針對廣東微容的11項訴訟的審判日期定為2021年6月30日。
此外,法院對集團的申請作出有利的裁定,以及為了保全財產,下令在2021年3月3日至2024年3月3日期間查封和凍結訴訟中所述廣東微容的專利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.